Genomic Landscape, Targeted Therapies, and Mechanisms of Resistance in Molecularly Selected Metastatic Colorectal Cancer Patients
Genes · 2026
DOI: 10.3390/genes17040460 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Genes, 2026. Verfasst von Patricia Garcia Pastor und 11 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, Vall d'Hebron University Hospital, 08035 Barcelona, Spain. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Drug Resistance, Neoplasm, Molecular Targeted Therapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 139 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Metastatic colorectal cancer (mCRC) remains one of the leading causes of cancer-related mortality worldwide despite substantial therapeutic improvements over the past two decades. Advances in the understanding of colorectal tumor biology and oncogenic signaling have enabled the development of biomarker-guided therapies targeting alterations in EGFR, BRAFV600E, KRAS mutations and HER2 amplifications, improving outcomes in selected patient populations. Nevertheless, the emergence of both intrinsic and acquired resistance mechanisms continues to limit the durability of these responses. Resistance to targeted therapies in mCRC arises through multiple, often convergent mechanisms, including activation of compensatory signaling pathways, pre-existing genomic heterogeneity, and therapy-driven clonal selection. The integration of molecular profiling into clinical decision-making is essential to guide treatment selection and optimize therapeutic sequencing, ultimately enabling progress in precision oncology. Advances in genomic technologies, particularly circulating tumor DNA (ctDNA) analysis, have allowed longitudinal monitoring of tumor evolution, providing important insights into the mechanisms underlying resistance to targeted therapies. The aim of this review is to summarize the genomic landscape of mCRC and discuss current targeted therapeutic strategies in molecularly defined subgroups, with a particular focus on the mechanisms driving primary and acquired resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Oncology Department, Vall d'Hebron University Hospital, 08035 Barcelona, Spain.
- Colorectal Cancer Group, Digestive Tumors Group, Vall d'Hebron Institute of Oncology, VHIO, 08035 Barcelona, Spain.
- Department of Hematology, Oncology, and Molecular Medicine, Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Piazza Ospedale Maggiore, 3, 20162 Milan, Italy.
ORCID-Profile: Francesc Salva, Javier Ros, Iosune Baraibar, Marta Rodríguez Castells, Adriana Alcaraz, Caterina Vaghi, Josep Tabernero
Zitieren
APA
Garcia Pastor, P., Saoudi González, N., Salva, F., Ros, J., Baraibar, I., Rodríguez Castells, M., Salva de Torres, C., García, A., Alcaraz, A., Vaghi, C., Tabernero, J., & Elez, E. (2026). Genomic Landscape, Targeted Therapies, and Mechanisms of Resistance in Molecularly Selected Metastatic Colorectal Cancer Patients. Genes. https://doi.org/10.3390/genes17040460
Vancouver
Garcia Pastor P, Saoudi González N, Salva F, Ros J, Baraibar I, Rodríguez Castells M, et al. Genomic Landscape, Targeted Therapies, and Mechanisms of Resistance in Molecularly Selected Metastatic Colorectal Cancer Patients. Genes. 2026. doi:10.3390/genes17040460
BibTeX
@article{GarciaPastor2026,
author = {Garcia Pastor, Patricia and Saoudi González, Nadia and Salva, Francesc and Ros, Javier and Baraibar, Iosune and Rodríguez Castells, Marta and Salva de Torres, Clara and García, Ariadna and Alcaraz, Adriana and Vaghi, Caterina and Tabernero, Josep and Elez, Elena},
title = {Genomic Landscape, Targeted Therapies, and Mechanisms of Resistance in Molecularly Selected Metastatic Colorectal Cancer Patients},
journal = {Genes},
year = {2026},
doi = {10.3390/genes17040460}
}
EUVIMED